Home/Filings/4/0000950170-25-048049
4//SEC Filing

Jacobs Bruce N. 4

Accession 0000950170-25-048049

CIK 0001815442other

Filed

Mar 31, 8:00 PM ET

Accepted

Apr 1, 8:00 AM ET

Size

6.8 KB

Accession

0000950170-25-048049

Insider Transaction Report

Form 4
Period: 2025-03-31
Jacobs Bruce N.
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-03-31$2.08/sh+25,000$52,000226,886 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-03-3125,00069,899 total
    Exercise: $2.08Exp: 2029-08-28Common Stock (25,000 underlying)
Footnotes (1)
  • [F1]Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares vested in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Documents

1 file

Issuer

Kymera Therapeutics, Inc.

CIK 0001815442

Entity typeother

Related Parties

1
  • filerCIK 0001821074

Filing Metadata

Form type
4
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 8:00 AM ET
Size
6.8 KB